The use of PRP injections in the management of knee osteoarthritis by Brendan O’Connell (7212632) et al.
REVIEW
The use of PRP injections in the management of knee osteoarthritis
Brendan O’Connell1 & Nicholas Martin Wragg2 & Samantha Louise Wilson2
Received: 3 May 2018 /Accepted: 11 January 2019 /Published online: 13 February 2019
# The Author(s) 2019
Abstract
Osteoarthritis (OA) is a degenerative disease involving joint damage, an inadequate healing response and progressive deterio-
ration of the joint architecture that commonly affects the knee and/or hip joints. It is a major world public health problem and is
predicted to increase rapidly with an ageing population and escalating rate of obesity. Autologous blood-derived products possess
much promise in the repair and regeneration of tissue and have important roles in inflammation, angiogenesis, cell migration and
metabolism in pathological conditions, including OA. Utilising platelet-rich plasma (PRP) to treat tendon, ligament and skeletal
muscle has shown variable results across many studies with the current evidence base for the efficacy of PRP in treating sports
injuries remaining inconclusive. More uniformly positive results have been observed by various studies for PRP in OA knee in
comparison to hyaluronic acid, other intra-articular injections and placebo than in other musculoskeletal tissue. However,
methodological concerns as well as satisfactory PRP product classification prevent the true characterisation of this treatment.
Thus, further research is required to investigate how leukocyte inclusion, activation and platelet concentration affect therapeutic
efficacy. Furthermore, the optimisation of timing, dosage, volume, frequency and rehabilitation strategies need to be ascertained.
For knee OA management, these concerns must be addressed before this promising treatment can be widely implemented.
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Introduction
Osteoarthritis (OA) is a serious degenerative joint disease
resulting from the degradation of articular cartilage, degrada-
tion and proliferative reformation of subchondral bone and a
low degree of synovitis that leads to a reduced quality of life
(QoL). It is a major cause of pain and disability in the elderly
population (> 70 years) (Neogi and Zhang 2013). OA alters
the normal joint metabolism favouring increased catabolism
and decreased anabolism (Dhillon et al. 2017). Inflammation
and vascular pathology, in combination with cell death,
meniscal changes, bone remodelling and subchondral sclero-
sis, produces a vicious cycle of progressive joint degeneration.
This can be exacerbated by excessive mechanical stress and
oxidative damage (Wruck et al. 2011). Moreover, under con-
ditions of metabolic or cytotoxic stress, such as in ageing,
autophagy can be upregulated, further decompensating ho-
meostatic mechanisms (Lotz and Caramés 2011).
In OA knees (Fig. 1), chondrocyte senescence and loss
of cartilage integrity are major features. There is an in-
crease in the water content of hyaline cartilage, accompa-
nied by corresponding decreases in proteoglycan concen-
tration, length and aggregation, causing reduced cartilage
stiffness and fibrillation of the cartilage surface. From
this, cartilage proceeds to erode and deep clefts may form.
Concurrently, morphological changes in subchondral bone
are found. As synovial fluid infiltrates, the formation of
subarticular cysts in the subchondral bone also occurs.
Osteophytes (bony projections) are characteristic features
of knee OA in non-pressure areas, caused by the flatten-
ing of bone from pressure in high-wear areas (Adatia et al.
2012).
Many interacting factors have a role in indicating the poten-
tial for the development of knee OA, although age is typically
highlighted (Blagojevic et al. 2010;Michael et al. 2010; Heidari
2011; Silverwood et al. 2015; Driban et al. 2017) (Table 1).
Primary care databases from a variety of countries have
shown a higher incidence of knee OA than hip or hand OA
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and a large increase in new knee OA diagnoses in the past
decade, especially in 35–44 year olds (Prieto-Alhambra et al.
2014; Yu et al. 2015). Over a 7-year period, an estimated 13%
of older adults (> 50 years) receive a diagnosis of OAwith the
knee joint implicated in 25% of the population (Jordan et al.
2014). There is also an accompanying socioeconomic burden in
terms of cost of medical care for both government and individ-
uals (Xing et al. 2017). It is a major public health problem
worldwide (Pereira et al. 2011) and is projected to rapidly in-
crease as the population ages and rates of obesity escalate
(Cross et al. 2014).
Hip and knee OA has been ranked as the 11th highest
contributor to global disability and 38th highest in years lived
with disability (Cross et al. 2014). The disability associated
with knee OA results in a considerable economic burden, both
in direct costs related to treatment, particularly joint replace-
ment surgery and job-related indirect costs, including loss of
productivity (Murphy and Helmick 2012). Knee OA affects
between 6% and 40% of the general population (Michael et al.
2010) and is significantly increased among retired elite ath-
letes, with prevalence rates as high as 95% (Gouttebarge et al.
2015). The global burden of knee OA, as rated by the World
Health Organisation (WHO, 2011), is comparable with that of
patients with cardiac dysrhythmias, liver cirrhosis or stage IV
kidney disease (Mather III et al. 2013).
Current knee osteoarthritis incidence
and management strategies
Knee OA management strategies include improvement in
function, reduction in disability, pain relief and hence, im-
proved QoL (Ng et al. 2012; Xing et al. 2017). However, there
currently exist no pharmacologic agents that are able to halt
OA progress ion or to reverse ex i s t ing damage
(Kanchanatawan et al. 2016). Existing approaches focus on
preventing or delaying progression by developing less inva-
sive procedures or applying interventions earlier in the disease
onset (Zhang et al. 2008). Non-operative therapeutic interven-
tions involving intra-articular injection at the knee joint, in-
cluding hyaluronic acid (HA), corticosteroids, platelet-rich
plasma (PRP), non-steroidal anti-inflammatory drugs
(NSAIDs), physical therapy and unloaded bracing, play major
roles in the management of knee OA (Campbell et al. 2015).
Fig. 1 Comparison of a healthy (left) and OA knee joint (right)
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Platelet-rich plasma for inducing
regeneration
PRP is an autologous mixture of highly concentrated platelets
and associated growth factors and other bioactive components
produced by centrifugal separation of whole blood (Fig. 2)
that is used in orthopaedic and sports medicine practices to
treat bone, tendon and ligament injuries (Fig. 3) (Sundman
et al. 2014). The growth factors released by PRP have been
discussed in great detail within the literature (Lubkowska et al.
2012; Pavlovic et al. 2016; Fernandes and Yang 2016; Parrish
and Roides 2018) and have been shown to promote cell
recruitment, proliferation and angiogenesis resulting in a re-
duction in the critical regulators of the inflammatory process
and a decrease in the expression of inflammatory enzymes
(Table 2) (van Buul et al. 2011). PRP may induce a
regenerative response by improving the metabolic
functions of damaged structures (Ficek et al. 2011; Chen
et al. 2018) and has been shown to have a positive effect on
chondrogenesis and mesenchymal stem cell proliferation
(Kabiri et al. 2014).
In clinical practice, PRP is used to enable the application of
autologous plasma and platelet-derived proteins to a desired
location with the use of an appropriate scaffold to assist in the
repair of the injured tissue (Marx 2001). The rationale for PRP
in scaffolds is to take advantage of the huge amount of growth
factors contained in platelets to promote cartilage regenera-
tion; however, the use of PRP-augmented scaffolds is still in
a preliminary state, with a low scientific level of power (Kon
et al. 2013). In application to chondrocytes, growth factors
promote matrix synthesis, cell growth and migration and fa-
cilitate protein transcription. The supra-physiological release
of platelet-derived factors directly at the site of cartilage dis-
ease, particularly with interest to knee OA, may stimulate the
natural regenerative signalling cascade and enhance the
healing of tissue with further mediation of the anti-
inflammatory response (Mascarenhas et al. 2014). In OA
joints, PRP has been shown to affect local and infiltrating
cells, mainly synovial cells, endothelial cells, those cells in-
volved in innate immunity (such as macrophages) and carti-
lage and bone cellular components (Mifune et al. 2013;
Dhillon et al. 2017). Additionally, PRP can affect inflamma-
tion and angiogenic processes and anabolism and catabolism
balance in cartilage formation and alter the existing microen-
vironment during disease progression (Andia and Maffulli
2013).
The combined effects of PRP make it a potential option
for management of knee OA, especially as a primary anal-
gesic agent (Meheux et al. 2016). This is due to an increase
in proliferation of tenocytes, osteoblasts, mesenchymal
stem cells resulting in decreased pain levels postoperative-
ly (Ogino et al. 2006). Despite encouraging preclinical re-
sults and increasing clinical interest, there remain multiple
questions regarding the clinical application and efficacy of
PRP, not least in the production of PRP, which can cause
wildly varying characteristics. A simple classification was
first proposed in 2009 following the fibrin architecture and
cell content (pure PRP: leukocyte-poor PRP, leukocyte-
and platelet-rich plasma; pure platelet-rich fibrin:
leukocyte-poor platelet-rich fibrin, leukocyte- and
platelet-rich fibrin). Each of these classifications had dif-
ferent growth factor release profiles (time, concentration)
but studies found additional biological signatures and
mechanisms within each family (Dohan Ehrenfest et al.
2014). A further classification can be included in the meth-
od of application (e.g., injections, glues) and the area of
application (e.g., oral/maxillofacial surgery, skin wound
healing). A more recent classification system called PAW
(platelet, activation, white blood cells) is based upon abso-
lute number of platelets, activation method and presence or
absence of white blood cells (DeLong et al. 2012).
According to the authors, the specific determination of
the components of the PRP is vital in allowing compari-
sons between studies. In 2016, a further classification was
Table 1 Risk factors for knee OA
Intrinsic Extrinsic
Age Previous trauma
• Advancing age effects of both
sexes altered locomotor
(stereognostic) control of
opposing muscle groups
• Macrotrauma
• Repetitive loading (e.g., squatting)
causing repetitive microtrauma
• Increases risk 3.86 times
Sex Co-morbidity
• Females more prone to develop
Heberden’s nodes, being female
increases risk 1.84 times
• Diseases such as:
▪ Cardiovascular disease
▪ Respiratory illness can
contribute/accelerate
progression of knee OA
Heredity Body mass
• Heberden’s nodes inherited as
autosomal trait
•Genetically determined metabolic
disorders (e.g., ochronosis and
Ehler-Danlos syndrome)
predispose to OA
• Overweight (BMI > 25)
• Obesity (BMI > 30)
Ethnic origins
• Increased incidence in European
descent
Resective joint surgery
• Less common in Asians
• Post-menopausal changes
Knee characteristics:
▪ Joint laxity Number of pregnancies (> 6)
▪ Malalignment (femur-tibial
angle (FTA))
Muscle weakness
Modified from Adatia et al. (2012)
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proposed. Magalon et al. (2016) suggested that the dose of
injected platelets, the efficiency of the production (percent-
age of platelets recovered), the purity of the PRP (ratio of
platelets, leucocytes and red blood cells) and the activation
process were overall termed the DEPA (dose, efficiency,
purity, activation) system. Whilst each of these systems has
their merits, as a product for application in the clinic, they
must be able to be characterised by the administrator or be
detailed on the product, in which case, the effect of storage/
transport should be disclosed in studies and discussed fur-
ther in the literature.
Current use of PRP in musculoskeletal tissues
PRP has been proposed as a promising biologic treatment
with a wide range of applications in sports medicine
(Lansdown and Fortier 2017). Injury type is significant,
wi th benef i ts shown in the t rea tment of pate l la
tendinopathy (Dragoo et al. 2014) and OA (Laudy et al.
2015) but not in Achilles tendinopathy or hamstring inju-
ries (Manduca and Straub 2018). The available clinical
studies on PRP as a treatment option suggest a good poten-
tial in favouring pain reduction and improved function for
articular injuries to the ankle, knee and hip (Engebretsen
et al. 2010). The evidence base for PRP across different
injury types has been criticised for being inconsistent and
uncertain (McNamee et al. 2018). In a meta-analysis,
Grassi et al. (2018) advocated PRP treatment as a safe pro-
cedure with negligible adverse effects that is readily avail-
able and has a minimal risk of reactivity compared to other
exogenous compounds owing to the autologous nature of
PRP injections. However, existing large and indiscriminate
use of PRP injections for the treatment of acute muscle
injuries in clinical practice is not justified by evidence
(Grassi et al. 2018). Thus, caution should be applied to
use in knee OA.
In muscle strain and tendon injuries, no statistical or
clinically significant differences were found for RTP dura-
tion and re-injury rate, leading to the conclusion that PRP
is no more effective than a placebo injection or intensive
rehabilitation (de Vos et al. 2010, 2014; Creaney et al.
2011; de Jonge et al. 2011; Thanasas et al. 2011; Krogh
et al. 2013; Hamilton et al. 2015; Reurink et al. 2015;
Liddle and Rodríguez-Merchán 2015); however, other
studies have pointed to enhanced recovery (A Hamid
et al. 2014; Chen et al. 2018). Between these reports, sig-
nificant differences in the quality of the study are noted and
should be used as a guide when analysing knee OA
efficacy.
In knee OA, PRP injections aim to stimulate cartilage
repair and offer relief to other osteoarthritic symptoms,
potentially delaying the need for joint replacement surgery.
PRP injections have shown to influence the entire joint
environment, leading to a short-term clinical improvement
(Filardo et al. 2012a, b) with PRP injections being
Fig. 2 PRP preparation process
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considered a safe procedure with more favourable out-
comes when compared to alternative treatments (Laver
et al. 2017). PRP is relatively easy to use due to its simple
and rapid preparation and the minimally invasive adminis-
tration requiring a simple intra-articular injection. Adverse
effects are likely to be reduced due to the patient’s own
protein use and bioactive molecules can be concentrated
to achieve the desired dosage, also eliminating potential
drug interactions (Zhu et al. 2013). Without a synthetic
element, PRP is, for the most part, not considered to be a
drug or therapeutic substance and does not therefore need
to fulfil the regulatory requirements needed for other bio-
logic therapies.
PRP use in knee osteoarthritis
The use of PRP in the treatment of degenerative knee OA has
increased in recent years given its apparent high margin of
safety and ease of production and administration (Smith
2016). Contrasting scientific evidence exists regarding PRP
injections for knee OA, with the efficacy of PRP injections
widely reported (Rahimzadeh et al. 2018). The enhanced ef-
fectiveness of PRP for pain treatment and knee joint function
in comparison to HA or placebo and positive outcomes in all
stages of knee OA (early, middle and late), have all been
reported (Kanchanatawan et al. 2016; Dai et al. 2017; Cole
et al. 2017). In addition, the effects of PRP seemingly last
Fig. 3 Clinical applications of PRP
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longer and are superior in comparison with intramuscular in-
jection therapies (Prieto-Alhambra et al. 2014). Comparisons
between intra-articular injection of PRP and placebo and HA
therapy in mild and moderate knee OA have generally shown
higher clinical outcome scores with PRP use (Filardo et al.
2012a, b). Similarly, using meta-analysis to compare the effi-
cacy of PRP injections against placebo or other therapeutic
means for the treatment of knee OA (Bennell et al. 2017)
has reported greater pain reduction (Laudy et al. 2015) and
functional improvement (Chang et al. 2014) with the use of
PRP. However, this is at the expense of an increase in nonspe-
cific adverse events (Khoshbin et al. 2013).
PRP use has been advocated as a treatment option in all
stages of knee OA. Intra-articular PRP injections in active
patients with knee OA show significant improvements in pain
reduction, improved symptoms and QoL (Gobbi et al. 2012).
This could be due to the immediate and sustained release of
growth factors over a prolonged period, which enhances
healing resulting in sustained clinical effects (Dhillon et al.
2017). Symptomatic relief for up to 12 months with increased
benefits to patients with early knee degenerative changes has
been found (Campbell et al. 2015) with significant improve-
ments in function and reductions in pain with three injections
per month yielding significantly better outcomes in the short-
term (Huang et al. 2017). Improved pain outcomes after
3 months with a greater effect in lower OA grades have been
reported (Montañez-Heredia et al. 2016). In moderate knee
OA, functional status and pain have improved with a mini-
mum of two injections (Kavadar et al. 2015). In late-stage
knee OA, it may be that only a single PRP intra-articular
injection is required to provide effective pain relief, thus
improving activities of daily living and QoL (Joshi Jubert
et al. 2017).
Research into the efficacy of PRP has focused on compar-
ing the effects of intra-articular PRP injections to other injec-
tion therapies. In many studies, PRP injections have improved
functional outcomes when compared to HA and placebo con-
trols and appear more efficacious in reducing symptoms and
improving QoL (Raeissadat et al. 2015; Kanchanatawan et al.
2016). Kon et al. (2011) examined three homogenous groups
of patients treated with three injections of PRP, low molecular
weight HA and high molecular weight HA and concluded that
autologous PRP injections have longer efficacy than HA in-
jections and enhance articular function. The results showed
improved outcomes for the PRP group at 6 months with youn-
ger and more active patients achieving better results with a
low degree of cartilage degeneration (Meheux et al. 2016).
Conversely, PRP causes a significantly greater acute inflam-
matory response and an increase in synoviocyte cell death
(Braun et al. 2014) and induces more transient reactions than
HA (Riboh et al. 2016). Spaková et al. (2012) compared three
PRP injections with three HA injections in a randomised con-
trolled trial (RCT) on 120 patients and discovered better
Western Ontario and McMaster Universities Arthritis Index
(WOMAC) scores and Numerical Rating Scale (NRS) in the
PRP group compared to the HA group (Table 3). In a separate
RCTwith 120 patients, Cerza et al. (2012) compared four PRP
injections at 1-week intervals with low molecular weight HA
and observed better improvement of WOMAC scores at
24 weeks in the PRP group. No correlations with the grade
of OA were found in either study. Additionally, better
WOMAC scores were achieved at 24 weeks using PRP by
Table 2 Commonly discussed
growth factors and effects
associated with PRP
Growth factor Effect
Platelet-derived growth factor
(PDGF)
Angiogenesis; macrophage activation; proliferation and chemotaxis of
fibroblasts; collagen synthesis; enhanced proliferation of bone cells
Transforming growth factor-β
(TGF-β)
Fibroblasts proliferation; synthesis of type I collagen and fibronectin;
deposition of bone matrix; inhibition of bone resorption
Platelet-derived epidermal growth
factor (PDGF)
Epidermal regeneration; promotes wound healing through stimulation of
keratinocytes and dermal fibroblasts proliferation; enhanced
production
and effect of other growth factors
Vascular endothelial growth factor
(VEGF)
Vascularisation; stimulation of vascular endothelial cells
Insulin-like growth factor 1 (IGF-I) Fibroblasts chemotaxis; protein synthesis stimulation; enhanced bone
formation
Platelet factor 4 (PF4) Enhanced influx of neutrophils; chemoattractant for fibroblasts
Epidermal growth factor (EGF) Cellular proliferation and differentiation
Hepatocyte growth factor (HGF) Inhibition of NF-κB transactivation activity; anti-inflammatory action
through inhibition of monocyte-like chemotaxis
Stromal-cell-derived growth
factor-1α (SDF-1α)
Supports primary adhesion and migration of progenitor cells
Modified from (Engebretsen et al. 2010)
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Sánchez et al. (2012) who examined 126 patients in a RCT
with different grades of OA and compared three PRP injec-
tions at 1-week intervals with HA. Similarly, better outcomes
have been documented when comparing PRP to HA groups at
6 months (Li et al. 2011; Say et al. 2013). Patel et al. (2013)
compared normal saline with PRP and demonstrated that PRP
significantly improved WOMAC scores following 6 months
in comparison to the placebo groups, with patients experienc-
ing benefits as early as 18 days. In a follow-up study, Patel and
Dhillon (2014) hypothesised that the anti-inflammatory effect
and chondral remodelling induced by PRP could be the reason
for the improved clinical effects.
Limitations and recommendations for further
research
Despite the apparent positivity in the use of PRP for treatment
of knee OA, methodological concerns and considerable het-
erogeneity between studies are evident (Rodriguez-Merchan
2013b). Large RCTs are needed to further assess the efficacy
and duration of PRP treatment for patients with knee OA
(Rodriguez-Merchan 2013a; Lai et al. 2015). When planning
or analysing treatments, frequency and number of injections,
as well as the activation methods (in the case of anticoagulated
PRP), storage aspects, time from plasma isolation and accom-
panying therapy should be considered as at present they vary
widely between groups. The greatest limiting factor for PRP
use is the lack of standardisation with further research required
to investigate how leukocyte inclusion, activation and platelet
concentration affect therapeutic efficacy (Chen et al. 2018).
Potential classification systems are discussed in depth by
Dohan Ehrenfest et al. (2014), Lana et al. (2017) and Alves
and Grimalt (2018). The cost-effectiveness of PRP, the demo-
graphic most likely to benefit and the optimal PRP protocol
must all be researched further (Bennell et al. 2017). To this
end, optimisation is still required regarding timing, dosage,
volume, frequency, composition and post-injection rehabilita-
tion (Engerbresten et al. 2010) and a unified classification
needs to be agreed before this promising treatment can be
widely implemented.
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Table 3 Methods to assess
impact of clinical intervention Outcome measure Function
Western Ontario and McMaster
Universities Osteoarthritis
Index (WOMAC)
Assesses pain, stiffness and physical function. Consists of 24 items
divided into 3 subscales:
• Pain (5 items): during walking, using stairs, in bed, sitting or lying
and standing
• Stiffness (2 items): following waking and later in the day
• Physical function (17 items): stair use, rising from sitting, standing,
bending, walking, getting in/out of a car, shopping,
putting on removing socks, rising from bed, lying in bed, getting
in/out of bath, sitting, getting on/off toilet, heavy household duties,
light household duties
Lequesne Assesses the effectiveness of therapeutic interventions.
Sections for index:
1. Pain or discomfort
2. Maximum distance walked
3. Activities of daily living
EQ-VAS Patients’ self-evaluation of overall health. 0 (worst possible health)
to 100 (best possible health)
International Knee Documentation
Committee (IKDC) Questionnaire
Subjective overall function score. Questionnaire looks at 3 categories:
• Symptoms
• Sports activity
• Knee function
Symptom subscale assists evaluation of pain, stiffness, swelling and
giving-way of the knee. Sports activity subscale focuses on functions
such as ascending and descending stairs, rising from a chair,
squatting and jumping.
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